Vivani Medical Inc(VANI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:31 PM ET (Korea 10/31 07:31)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.36 | Insider Own | 58.05% | Shs Outstand | 89.4M | Perf Week | -1.8% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | -37.88% | Insider Trans | 8.2% | Shs Float | 37.8M | Perf Month | -10.66% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.09 | Inst Own | 5.76% | Short Float | 1.1% | Perf Quarter | -18.05% |
| Income | -0.03B | P/S | - | EPS this Y | 23.26% | Inst Trans | -3% | Short Ratio | 2.19 | Perf Half Y | -19.85% |
| Sales | 0.00B | P/B | 5.14 | EPS next 5Y | 2.38% | ROA | -74.6% | Short Interest | 0.42M | Perf YTD | -11.38% |
| Book/sh | 0.21 | P/C | 4.94 | EPS past 3/5Y | -5.5% 27.77% | ROE | -220.4% | 52W High | -39.44% ($1.80) | Perf Year | -35.5% |
| Cash/sh | 0.22 | P/FCF | - | Sales past 3/5Y | - | ROIC | -75.22% | 52W Low | 18.13% ($0.92) | Perf 3Y | 0.93% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.38% | Gross Margin | - | Volatility(W/M) | 6.14% 4.61% | Perf 5Y | -86.74% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | -98.35% |
| Dividend Ex-Date | - | Quick Ratio | 3.25 | EPS Q/Q | 39.39% | Profit Margin | - | RSI (14) | 35.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.25 | Sales Q/Q | - | SMA20 | -6.24% ($1.16) | Beta | 2.5 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.94 | Earnings | 2026/8/13 | SMA50 | -12.65% ($1.25) | Rel Volume | 1.05 | Prev Close | $1.14 |
| Employees | 42 | LT Debt/Eq | 0.84 | EPS/Sales Surpr. | 15.97% - | SMA200 | -13.26% ($1.26) | Avg Volume(3M) | 0.19M | Price | $1.09 |
| IPO | 2014/11/19 | Option/Short | Yes/Yes | Trades | 860 | Volume | 199,270 | Change | -4.39% |
Vivani Medical is a clinical-stage biopharmaceutical company developing ultra-long-acting drug implants. Leveraging its proprietary NanoPortal technology, the company is researching implantable therapies designed to address medication adherence challenges in chronic disease areas such as obesity and type 2 diabetes. Headquartered in the US, Vivani Medical is focused on its glucagon-like peptide (GLP) implant pipeline.
Over the past 1 year, on the lower side
39% below its 1-year high.
Traded about as much as usual. That is 105% of its average volume.
VANI has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +23.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #358 of 597 in the industry
Based on market cap of $98M.
PMVP#356 PMV Pharmaceuticals Inc $99M PER - 
CBUS#357 Cibus Inc $99M PER - VANI#358 Vivani Medical Inc $98M PER - 
NRXP#359 NRX Pharmaceuticals Inc $98M PER - 
KZIA#360 Kazia Therapeutics Limited ADR $97M PER - 
FAQ
What kind of company is VANI?
VANI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VANI?
The market cap of VANI is approximately $98M, ranking 4,471 within its sector.
What is the 52-week high and low for VANI?
VANI has recorded a 52-week high of $1.80 and a low of $0.92.
